The size of the Asia Pacific IUD’s Market is estimated to grow USD 523.42 million by 2026 and USD 418.01 million in 2021, growing at a CAGR of 4.60% during the forecast period.
The rise of the intrauterine contraceptive devices (IUD) market is primarily due to technical improvements that have resulted in effective contraception with few to no adverse effects. With the rising number of measures taken by governments across the APAC to encourage the use of these devices as a result of the rising prevalence of unplanned pregnancies, the APAC intrauterine contraceptive devices market is anticipated to grow significantly during the forecast period. Another factor is the rise in unplanned pregnancies, aided by government measures to avoid unwanted pregnancies with; a growing awareness of the contraceptive is expected to augment the market growth. On the other hand, fewer adverse effects associated with intrauterine contraceptive devices would increase the number of chances for the intrauterine contraceptive devices market to expand throughout the projected period.
However, increased contraceptive awareness has contributed to a decrease in unintended pregnancies and the expansion of the contraception industry in recent years. Increased availability of intrauterine contraceptive devices and other family planning activities can help minimize unwanted pregnancies. In addition, the usage of IUDs reduced the number of unintended pregnancies. As a result, IUD use is increasing year after year as women discover it to be the most convenient, safe, and effective method of contraception. As a result, the market under consideration is projected to be fuelled by the rising number of unplanned pregnancies in Asian countries.
An unwanted conception is referred to as unintended pregnancy. An unplanned pregnancy can occur if contraception or contraceptive techniques are used incorrectly or not at all. Teenagers under the age of 18 had the highest rate of unplanned pregnancies, followed by women aged 20 to 24. These unintended births are directly contributing to the rise in contraceptive device demand. As a result, IUD use is rising year after year in APAC, as women discover IUDs to be a simple, safe, and efficient method of contraception. As a result, market research suggests that the global problem of unplanned pregnancies will be a key driving force. According to statistics collected over the last few years, more than half of pregnancies are mistimed, undesired, and unintentional. As a result, numerous governments and non-profit groups are encouraging the use of IUDs as well as teaching individuals about birth control and family planning methods. Additionally, the market is also supported by technological advancements such as reusable and postpartum IUDs, which are expected to enhance market development throughout the projected period.
Infertility, religious and cultural resistance, economic restrictions, ectopic pregnancy, pelvic inflammatory infection, and limited access to contraception are all challenges that are limiting the market's growth.
This research report segmented and sub-segmented the Asia-Pacific Intrauterine Devices Market into the following categories:
By Product:
By End User:
By Country:
Geographically, the Asia Pacific Intrauterine Devices Market is projected to grow at a significant rate over the forecast period. The major market growth contributors such as China and India are holding the largest share of the market. In the recent period, it has been observed that more than half of the pregnancies are mistimed, unwanted and unintended. On account of this, several governments and non-profit organizations in the APAC region are promoting the use of IUDs in confluence with educating the people about birth control measures and family planning, which is expected to propel market growth.
In the regional market, China dominated the Intrauterine Devices Market during the previous years. The market growth is majorly augmented owing to the technological advancements in the healthcare sector and advancing healthcare infrastructure.
The Indian intrauterine device market is one of the promising markets in the Asia Pacific over the years, and it is anticipated to witness substantial Share and contribute to the APAC regional market growth during the forecast period. the market growth is aided by government measures to avoid unwanted pregnancies with; a growing awareness of the contraceptive.
KEY MARKET PLAYERS:
Notable companies leading the Asia-Pacific Intrauterine Devices Market are Agile Therapeutics, Actavis PLC, ANI Pharmaceuticals Inc., Bayer, Teva Pharmaceutical, Besins HealthCare, Brecuro Medical, Effik International, Eurogine, HLL Lifecare, HRA Pharma, Lupin Pharmaceuticals, Ltd, Okamato Industries, Inc. and Pfizer.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Hormonal Intrauterine Devices
5.1.2 Copper intrauterine Devices
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Agile Therapeutics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Actavis PLC
8.3 ANI Pharmaceuticals
8.4 Bayer
8.5 Teva Pharmaceutical
8.6 Besins HealthCare
8.7 Brecuro Medical
8.8 Effik International
8.9 Eurogine
8.10 HLL Lifecare
8.11 HRA Pharma
8.12 Lupin Pharmaceuticals
8.13 Okamato Industries
8.14 Pfizer
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market outlook and Investment oppurtunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
